Quilizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Quilizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIGHE
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10046N1728O2023S44
Molar mass146.1 kg/mol g·mol−1

Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.[1] It binds to IGHE.[2][3][4][5][6][7]

This drug was developed by Genentech.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Quilizumab, American Medical Association.
  2. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
  3. ^ Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, Staubach P, Metz M, Sussman G, Maurer M (December 2016). "A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria". J. Allergy Clin. Immunol. 138 (6): 1730–1732. doi:10.1016/j.jaci.2016.06.023. PMID 27567329.
  4. ^ Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG (March 2016). "A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma". Respir. Res. 17: 29. doi:10.1186/s12931-016-0347-2. PMC 4797126. PMID 26993628.
  5. ^ Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM (July 2014). "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production". Sci Transl Med. 6 (243): 243ra85. doi:10.1126/scitranslmed.3008961. PMID 24990880.
  6. ^ Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL (March 2017). "An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases". Curr Respir Med Rev. 13 (1): 22–29. doi:10.2174/1573398X13666170616110738. PMC 5735517. PMID 29290750.
  7. ^ Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB (2018). "Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria". J Allergy Clin Immunol Pract. 6 (4): 1108–1117. doi:10.1016/j.jaip.2018.02.024. PMID 30033912.